NasdaqCM:PRQRBiotechs
ProQR Therapeutics Q4 Net Loss Of €8.9 Million Reinforces Profitability Concerns
ProQR Therapeutics (NasdaqCM:PRQR) has wrapped up FY 2025 with fourth quarter revenue of €4.7 million and a basic EPS loss of €0.08, alongside a net income loss of €8.9 million. These figures put hard numbers around where the business stands today. Over recent periods the company has seen quarterly revenue range from €2.9 million to €4.7 million, while quarterly basic EPS has moved between a loss of €0.12 and a loss of €0.08. As a result, the story for investors remains centered on how...